<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042130</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-16-HO-512-CTIL</org_study_id>
    <nct_id>NCT03042130</nct_id>
  </id_info>
  <brief_title>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency</brief_title>
  <official_title>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be
      randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The
      control group will receive standard of care alone. The study will test for the effects of the
      additional IV iron on the symptoms, clinical picture and quality of life of the treated
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be
      randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The
      control group will receive standard of care alone. The study will test for the effects of the
      additional IV iron on the symptoms, clinical picture and quality of life of the treated
      patients. The parameters that will be measured will include clinical, lab, echo, and quality
      of life questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no recruitment
  </why_stopped>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Actual">February 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functioning improvement</measure>
    <time_frame>5 days after second administration</time_frame>
    <description>NYHA assesment (New York Heart Association (NYHA) Functional Classification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life improvement</measure>
    <time_frame>5 days after second administration</time_frame>
    <description>KCCQ questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functioning improvement</measure>
    <time_frame>1 month after second administration</time_frame>
    <description>NYHA assesment (New York Heart Association (NYHA) Functional Classification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life improvement</measure>
    <time_frame>1 month after second administration</time_frame>
    <description>KCCQ (The Kansas City Cardiomyopathy Questionnaire)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard of care + double dose of IV iron ferinject
the medicine will be given twice within one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Carboxymaltose</intervention_name>
    <description>Two IV doses</description>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure grade 3-4

          -  Heart echo EF&lt; 40% (ejection fraction)

          -  Hb &gt; 10 mg/dL

          -  Iron&gt; 50 mic/dL

          -  Iron/ transferrin rate &gt; 20%

        Exclusion Criteria:

          -  Infection

          -  Acute ischemia

          -  Patients that didn't receive the standard of care during 3 days before investigational
             product administration

          -  Hemochromatosis

          -  Known allergy to one of the products of the investigational product.

          -  Macrocytic anemia

          -  Iron excess

          -  Pregnant women

          -  Mentally disabled patients which can't give their concent properly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Oster, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician - Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of internal medicine A</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

